These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 33888558)

  • 1. Interfaces between cellular responses to DNA damage and cancer immunotherapy.
    Pilger D; Seymour LW; Jackson SP
    Genes Dev; 2021 May; 35(9-10):602-618. PubMed ID: 33888558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The complementarity of DDR, nucleic acids and anti-tumour immunity.
    Kornepati AVR; Rogers CM; Sung P; Curiel TJ
    Nature; 2023 Jul; 619(7970):475-486. PubMed ID: 37468584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Function and Molecular Mechanism of the DNA Damage Response in Immunity and Cancer Immunotherapy.
    Ye Z; Shi Y; Lees-Miller SP; Tainer JA
    Front Immunol; 2021; 12():797880. PubMed ID: 34970273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting DNA Repair Response Promotes Immunotherapy in Ovarian Cancer: Rationale and Clinical Application.
    Xie H; Wang W; Qi W; Jin W; Xia B
    Front Immunol; 2021; 12():661115. PubMed ID: 34712221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.
    Brown JS; O'Carrigan B; Jackson SP; Yap TA
    Cancer Discov; 2017 Jan; 7(1):20-37. PubMed ID: 28003236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication.
    Lamberti G; Andrini E; Sisi M; Federico AD; Ricciuti B
    Future Oncol; 2020 Aug; 16(23):1751-1766. PubMed ID: 32539551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
    Cerrato A; Morra F; Celetti A
    J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy.
    Huang JL; Chang YT; Hong ZY; Lin CS
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of DNA damage repair and precise targeted therapy in renal cancer (Review).
    Lai Y; Li Z; Lu Z; Zheng H; Chen C; Liu C; Yang Y; Tang F; He Z
    Oncol Rep; 2022 Dec; 48(6):. PubMed ID: 36263616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATR Inhibition Induces CDK1-SPOP Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate Cancer.
    Tang Z; Pilié PG; Geng C; Manyam GC; Yang G; Park S; Wang D; Peng S; Wu C; Peng G; Yap TA; Corn PG; Broom BM; Thompson TC
    Clin Cancer Res; 2021 Sep; 27(17):4898-4909. PubMed ID: 34168048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.
    Gourley C; Balmaña J; Ledermann JA; Serra V; Dent R; Loibl S; Pujade-Lauraine E; Boulton SJ
    J Clin Oncol; 2019 Sep; 37(25):2257-2269. PubMed ID: 31050911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA Damage and Cancer Immunotherapy: A STING in the Tale.
    Reisländer T; Groelly FJ; Tarsounas M
    Mol Cell; 2020 Oct; 80(1):21-28. PubMed ID: 32810436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
    Gupta T; Vinayak S; Telli M
    Breast Cancer Res Treat; 2023 Jan; 197(1):51-56. PubMed ID: 36318381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers.
    Tolba MF; Elghazaly H; Bousoik E; Elmazar MMA; Tolaney SM
    Clin Transl Oncol; 2021 Oct; 23(10):1979-1994. PubMed ID: 33871826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations.
    Ngoi NYL; Westin SN; Yap TA
    Curr Opin Oncol; 2022 Sep; 34(5):559-569. PubMed ID: 35787597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP inhibitor plus radiotherapy reshape the immune suppressive microenvironment and potentiate the efficacy of immune checkpoint inhibitors in tumors with IDH1 mutation.
    Hu X; Zhao M; Bai M; Xue Z; Wang F; Zhu Z; Yu J; Yue J
    Cancer Lett; 2024 Apr; 586():216676. PubMed ID: 38278469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment.
    Genta S; Martorana F; Stathis A; Colombo I
    Crit Rev Oncol Hematol; 2021 Dec; 168():103539. PubMed ID: 34800653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment.
    Criscuolo D; Morra F; Giannella R; Visconti R; Cerrato A; Celetti A
    J Exp Clin Cancer Res; 2019 Feb; 38(1):91. PubMed ID: 30791940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting DNA damage response pathways in cancer.
    Groelly FJ; Fawkes M; Dagg RA; Blackford AN; Tarsounas M
    Nat Rev Cancer; 2023 Feb; 23(2):78-94. PubMed ID: 36471053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The DNA Damaging Revolution: PARP Inhibitors and Beyond.
    Yap TA; Plummer R; Azad NS; Helleday T
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():185-195. PubMed ID: 31099635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.